HCPLive Network

Dr. Kimme Hyrich Discusses Cancer Risk in RA Patients Receiving Anti-TNF Therapies

Rheumatology   |   Oncology   |  
Kimme L. Hyrich, MD, Arthritis Research UK Epidemiology Unit at University of Manchester, discusses the risk of rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy developing solid cancers.

“When they were first used and available for widespread use, there was a continuing anxiety about whether or not an agent which blocks tumor necrosis factor would actually increase the risk of cancer in patients with rheumatoid arthritis,” said Hyrich.

Related Videos
In this video, Raymond Cross, MD, associate professor of medicine and director of the Inflammatory Bowel Disease Program at the University of Maryland School of Medicine, discusses the latest strategies for treating ulcerative colitis at the annual scientific meeting of the American College of Gastroenterology in Washington, DC.
In this video, Barbara D. Alexander, MD, Associate Professor of Medicine, talks about anti-microbial resistance and the limited antibiotic pipeline represent a major global health threat.
Why rheumatoid arthritis drug trials are using the "non-inferiority" methodology instead of the typical method, according to Lee S. Simon, MD, principal with SDG, LLC.